The positive trial results for EYP-1901 are significant for EyePoint Pharmaceuticals, as they demonstrate the drug's efficacy and safety, which are critical for FDA approval and market adoption. The substantial reduction in treatment burden and the maintenance of strong anatomical control are particularly noteworthy. These factors, combined with the low patient discontinuation rate, suggest a competitive advantage in the market for wet AMD treatments. The stock's surge in premarket trading reflects investor optimism about the drug's commercial potential.